Latest News and Press Releases

Strong Annual Year-Over-Year Growth with 14% Revenue Growth Strong Quarter-Over-Quarter Growth with 20% Revenue Growth and 25% Reduction in Expenses Reduction in Annual Year-Over-Year Net Loss by...

PETALUMA, Calif., June 19, 2019 (GLOBE NEWSWIRE) -- Specialty pharmaceutical company Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced the timing for a 1-for-9 reverse split of its...

PETALUMA, Calif., May 21, 2019 (GLOBE NEWSWIRE) -- Specialty pharmaceutical company Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced the sale of certain animal health product rights and...

PETALUMA, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- Specialty pharmaceutical company Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced substantial cost-cutting measures, including...

CEO Jim Schutz and CFO Robert Miller Step DownFrederick (Bubba) Sandford Appointed as New CEO and Interim CFO and will Join the Board PETALUMA, Calif., Dec. 14, 2018 (GLOBE NEWSWIRE) -- Sonoma...

PETALUMA, Calif., Nov. 17, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the pricing of a “best efforts” public offering of units consisting of one share of...

• Total Revenue of $4.9 Million, up 13% over June 2018 Quarter• Total Revenue up 14% over September 2017 Quarter Conference Call Begins at 4:30 pm EST Today PETALUMA, Calif., Nov. 08, 2018 (GLOBE...

PETALUMA, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced that financial results for its fiscal year 2019 second quarter, ended September 30,...

PETALUMA, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced newly published results from a study into the use of the company’s proprietary...

PETALUMA, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company that develops and markets unique and effective solutions for the...